Great Britain
Resources for healthcare professionals
Spikevax bivalent Original/Omicron BA.4-5▼(50 micrograms/50 micrograms)/mL dispersion for injection
Spikevax bivalent Original/Omicron BA.4-5 is indicated as a booster dose for active immunisation to prevent COVID-19 caused by SARS-CoV-2 in individuals 12 years of age and older who have previously received at least a primary vaccination course against COVID-19.
Patient Information Leaflet
Summary of Product Characteristics
Direct Healthcare Professional Communication
Feb 23, 2023
Spikevax bivalent Original/Omicron BA.1▼(50 micrograms/50 micrograms)/mL dispersion for injection
A Conditional Marketing Authorisation (CMA) has been granted in the UK for Spikevax bivalent Original/Omicron as a booster dose for active immunisation to prevent COVID-19 caused by SARS-CoV-2 in individuals 6 years of age and older.
Patient Information Leaflet
Summary of Product Characteristics
Direct Healthcare Professional Communication
Nov 28, 2022
Direct Healthcare Professional Communication
Nov 04, 2022
Direct Healthcare Professional Communication
Sep 26, 2022
Direct Healthcare Professional Communication
Sep 12, 2022
Direct Healthcare Professional Communication
Sep 09, 2022
Direct Healthcare Professional Communication
Sep 07, 2022
Spikevax▼(previously COVID-19 Vaccine Moderna)
Spikevax is indicated for active immunisation to prevent COVID-19 caused by SARS-CoV-2 in individuals 6 years of age and older.
Patient Information Leaflet
Summary of Product Characteristics
Direct Healthcare Professional Communication
Sep 27, 2022
Direct Healthcare Professional Communication
Sep 07, 2022
Northern Ireland
Resources for healthcare professionals
Spikevax bivalent Original/Omicron BA.4-5▼(50 micrograms/50 micrograms)/mL dispersion for injection
Spikevax bivalent Original/Omicron BA.4-5 is indicated for active immunizsation to prevent COVID-19 caused by SARS-CoV-2 in individuals 12 years of age and older who have previously received at least a primary vaccination course against COVID-19.
Patient Information Leaflet
Summary of Product Characteristics
Direct Healthcare Professional Communication
Nov 28, 2022
Spikevax bivalent Original/Omicron BA.1▼(50 micrograms/50 micrograms)/mL dispersion for injection
Spikevax bivalent Original/Omicron BA.1 is indicated for active immunisation to prevent COVID-19 caused by SARS-CoV-2 in individuals 6 years of age and older who have previously received at least a primary vaccination course against COVID-19.
Patient Information Leaflet
Summary of Product Characteristics
Direct Healthcare Professional Communication
Nov 28, 2022
Direct Healthcare Professional Communication
Sep 29, 2022
Direct Healthcare Professional Communication
Sep 21, 2022
Direct Healthcare Professional Communication
Sep 12, 2022
Spikevax▼(previously COVID-19 Vaccine Moderna)
Spikevax is indicated for active immunisation to prevent COVID-19 caused by SARS-CoV-2 in individuals 6 months of age and older.
Patient Information Leaflet
Summary of Product Characteristics
Direct Healthcare Professional Communication
Sep 27, 2022
Adverse events should be reported. Reporting forms and information can be found at https://yellowcard.mhra.gov.uk/ or search for MHRA Yellow Card in the Google Play or Apple App Store and include the vaccine brand and batch/Lot number if available. They can also be reported to Moderna using the Adverse Event Intake Portal or by calling 0800 085 7562.
To report a product quality complaint or for general medical information inquiries, please contact Moderna on 0800 085 7562 or at EMEAMedinfo@modernatx.com
Contact Moderna
8am-5pm GMT – Mon - Fri
EMEAMedinfo@modernatx.com